Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful. The important notices at the end of this press release should be observed.

‍

Berlin, 28 November 2023 – Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01, www.cantourage.com/en), a leading European company for the production and distribution of medical cannabis, and Oceanic Releaf, an established Canadian company for the cultivation and distribution of high-quality cannabis products, are bringing medical cannabis to the European market together. Through the partnership with Cantourage, patients in Europe can now be prescribed the "Black Cookies" cultivar from Oceanic Releaf, which was grown on the pristine shores of the North Atlantic in the eastern Canadian province of Newfoundland and Labrador. In Germany, the cannabis product can now be accessed as a medical product from pharmacies.

‍

Since 2021, Oceanic Releaf has been manufacturing a range of cannabis products at its Health Canada-licensed cultivation facility on the Burin Peninsula in eastern Canada. These products are available for purchase under the company's three proprietary brands—Oceanic Premium Craft, Booty, and Seaweed—throughout over 100 retail locations across the country. Additionally, the company manages nine retail stores in the province of Newfoundland and Labrador.

‍

Taylor Giovannini, Founder and CEO of Oceanic Releaf, states: "The entry of Oceanic Releaf into the European market brings us back to our roots of medicinal cannabis. My enthusiasm for cannabis came about when a family member was ill, and I saw the great effect of the plant in relieving pain for the first time. I am very pleased that together with Cantourage we can now also distribute our products in Europe. This will help to ensure that even more people can benefit from the medical advantages of cannabis."

‍

Philip Schetter, CEO of Cantourage, states: "We are very pleased that an increasing number of growers want to enter the European medical cannabis market through our "Fast Track Access" platform. The platform enables growers worldwide to rapidly enter a strong growth market. Moving forward, we want to continue to expand and diversify our producer portfolio. Oceanic Releaf is an interesting and successful company with unique products. "

‍

About Oceanic Releaf
Oceanic Releaf stands as a well-established Canadian enterprise dedicated to the cultivation and distribution of top-tier cannabis products. Situated in the rural expanse of the Burin Peninsula in Newfoundland and Labrador, eastern Canada, the company presently manages nine retail establishments within this province. Covering approximately 5,800 square meters, Oceanic Releaf's licensed cultivation facility is positioned along the pristine shores of the North Atlantic, overseen by members of the local Burin community. The company places significant emphasis on ensuring its products epitomize the finest offerings of the province. Currently, Oceanic Releaf's three proprietary brands—Oceanic Premium Craft, Booty, and Seaweed—are available in numerous Canadian provinces and at over 100 points of sale nationwide.

For further information: oceanicreleaf.ca

‍

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH”.

For further information: www.cantourage.com/en

‍

This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

‍

Press contact at Cantourage:
Tonka Communications
+49 (0)176 7471 7519
cantourage@tonka-pr.com